Effect and safety of Kanglaite injection combined with chemotherapy in the treatment of advanced colorectal cancer:a systematic review and meta-analysis

Objective:To evaluate the clinical efficacy and safety of Kanglaite injection combined with chemotherapy and chemotherapy alone in the treatment of advanced colorectal cancer.Methods:PubMed,Cochrane library,CNKI,VIP,Wanfang database were systematically searched by inputting keywords to explore the efficacy of Kanglaite injection combined with chemotherapy in the treatment of advanced colorectal cancer.A random-effects model was selected to evaluate the treatment outcomes.The screening of literature,the extraction of data and the assessment of methodology were independently undertaken by two reviewers.Meta analysis was performed using Revman5.3 software and stata15.0 software.Results:A total of 12 RCTs were included,with 792 cases.Compared with chemotherapy alone,Metaanalysis suggested that Kanglaite injection combined with chemotherapy can improve clinical efficiency(RR=1.45,95%CI:1.21-1.74,P<0.0001)and improve patients'quality of life(RR=1.55,95%CI:1.32-1.82,P<0.00001),improve the patient's immune function(CD3+cells:SWD=1.42,95%CI:1.11-1.73;CD4+/CD8+cell ratio:SWD=0.95,95%CI:0.66-1.25;NK cell activity:SWD=3.24,95%CI:2.81-3.66,P<0.00001);Leukopenia rate(RR=0.63,95%CI:0.54-0.74,P<0.0001),incidence of gastrointestinal adverse reactions(RR=0.56,95%CI:0.48-0.66,P<0.00001),incidence of peripheral neurotoxicity(RR=0.79,95%CI:0.65-0.96,P=0.02)were lower than the chemotherapy alone group,the difference was statistically significant.In improving the hand-foot syndrome and oral mucositis after chemotherapy,there was some difference between the Kanglaite injection combined with chemotherapy group and the chemotherapy alone group,but the difference was not significant.Puber bias detection and sensitivity analysis were performed with clinically effective relative risk(RR)as indicators.The results suggested that the publication bias was not obvious.The results of this study are stable.Conclusion:Compared with chemotherapy alone group in the treatment of advanced colorectal cancer,Kanglaite injection combined with chemotherapy can improve the effective rate,quality of life,immune function of patients and reduce the incidence of leukopenia after chemotherapy,gastrointestinal adverse reactions and peripheral neurotoxicity.

Astragalus injection as an adjuvant treatment for colorectal cancer:a meta-analysis

Background:The combination of Chinese patent medicine Astragalus injection and Western medicine has achieved a certain clinical effect in colorectal cancer patients.However,due to the uneven basic conditions and research indicators of these clinical trials,it is difficult to comprehensively evaluate the effect of Astragalus injection in the adjuvant treatment of colorectal cancer.This study aimed to systematically evaluate the efficacy and safety of Astragalus injection as an adjuvant treatment for colorectal cancer.Methods:The Cochrane Library,VIP database,Wanfang database,and Chinese Academic Journal Full Text database were searched for potentially eligible articles from inception to December 15,2018.Randomized controlled trials in which patients were diagnosed with colorectal cancer were included.Patients in the control group received chemotherapy alone or combined with other drugs,or chemotherapy combined with radiotherapy.Patients in the experimental group were treated with Astragalus injection combined with interventions in the control group.Results:A total of 8 articles were included.Compared with Western medicine alone,the Astragalus injection could improve the therapeutic effect(RR=1.18,95%CI(1.01,1.38),P=0.03),improved the quality of life of colorectal cancer patients(SMD=1.18,95%CI(0.86,1.50),P<0.001),inhibited leukopenia(RR=0.55,95%CI(0.42,0.71),P<0.001),reduced neurotoxicity(RR=0.43,95%CI(0.34,0.56),P<0.001),and reduced the incidence of nausea and vomiting(RR=0.67,95%CI(0.55,0.80),P<0.001).Conclusion:Astragalus injection can reduce the toxicity and improve the efficiency of the conventional Western medicine in the treatment of colorectal cancer.

Literature on the law of Miao medicine in treating liver cancer

目的:通过苗族医学治疗肝癌药物文献整理分析,探讨苗族医学治疗肝癌的用药规律。方法:以《中华本草·苗药卷》为文献来源,拟定检索词对CNKI数据库、万方数据库建库至2018年5月苗族医药治疗肝癌的相关文献进行检索,符合条件的药物对其科属、药性、药味、归经及功效进行统计分析。结果:共纳入苗族医学治疗肝癌药物132味,高频科属为菊科、百合科、蔷薇科,共占22.8%;药性以冷药为主,占75.8%;药味以苦、辣、甜为主,共占75.5%;归经以热经、冷经为主,共占90.5%;功效以治毒药、补体药、通气散血药为主,共占80.4%。结论:苗族医学治疗肝癌谨守两纲理论之冷热辨证,在治毒的基础上合理运用补体药、通气散血药等标本兼顾。